Human deoxycytidine kinase (dCK) is responsible for the phosphorylation of a number of clinically important nucleoside analogue prodrugs in addition to its natural substrates, 2′-deoxycytidine, 2′-deoxyguanosine, and 2′-deoxyadenosine. To improve the low catalytic activity and tailor the substrate specificity of dCK, we have constructed libraries of mutant enzymes and tested them for thymidine kinase (tk) activity. Random mutagenesis was employed to probe for amino acid positions with an impact on substrate specificity throughout the entire enzyme structure, identifying positions Arg104 and Asp133 in the active site as key residues for substrate specificity. Kinetic analysis indicates that Arg104Gln/Asp133Gly creates a "generalist" kinase with broader specificity and elevated turnover for natural and prodrug substrates. In contrast, the substitutions of Arg104Met/ Asp133Thr, obtained via site-saturation mutagenesis, yielded a mutant with reversed substrate specificity, elevating the specific constant for thymidine phosphorylation by over 1000-fold while eliminating activity for dC, dA, and dG under physiological conditions. The results illuminate the key contributions of these two amino acid positions to enzyme function by demonstrating their ability to moderate substrate specificity.Human deoxycytidine kinase (dCK; 1 EC 2.7.1.74) catalyzes the phosphorylation of 2′-deoxycytidine (dC), 2′-deoxyadenosine (dA) and 2′-deoxyguanosine (dG) to their corresponding monophosphates using nucleoside triphosphates as phosphoryl donors. This reaction is the first step of the deoxyribonucleoside salvage pathway, an alternative to de novo nucleotide biosynthesis, which, in combination with deoxyribonucleoside mono-and diphosphate kinases, provides triphosphate anabolites for DNA replication and repair (1).In addition to recycling natural 2′-deoxyribonucleosides, dCK catalyzes the initial, often ratedetermining phosphorylation of several chemotherapeutic nucleoside analogue (NA) prodrugs such as gemcitabine (2′,2′-difluorodeoxycytidine), AraC (1-β-D-arabinosylcytosine), and clofarabine [2-chloro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)-9H-purin-6-amine], as well as antiviral prodrugs including ddC (2′,3′-dideoxycytidine), 3TC (2′-deoxy-3′-thiacytidine), and FTC (5-fluoro-2′-deoxy-3′-thiacytidine) whose pharmacological activity depends on their triphosphate form (2-7). Given the critical role of dCK in phosphorylating 2′- † The authors would like to acknowledge financial support in part by NIH Grant GM69958 and by a grant to the Emory Center for AIDS Research (AI050409) from the NIH and by institutional funding from the Emory University Health Science Center. *Corresponding author: Department of Chemistry, Emory University, 1515 Dickey Drive, Atlanta, GA 30322. Tel: (404) 712-2170. Fax: (404) 727-6586. E-mail: sal2@emory.edu. SUPPORTING INFORMATION AVAILABLE Oligonucleotide sequences used as primers for the site-directed mutagenesis (Table S-1) and statistical data on the codon distribution of the site-saturation mutage...